Calypte Only Company with Full Menu of Tests.

ist das der Michael A. Roth vom 1.FCN !!!!!!!!!!!!!!!!!  

 

SC 13G/A
1
feb_13ga-calypte.txt
ROTH-STARK\2006\FEB 13GAS\FEB 13GA-CALYPTE

                      SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, DC 20549

                                 SCHEDULE 13G
                                (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES
    13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

                              (Amendment No. 2)*

                        Calypte Biomedical Corporation
                        ------------------------------
                               (Name of Issuer)

                    Common Stock, par value $0.03 per share
                    ---------------------------------------
                        (Title of Class of Securities)

                                   131722100
                                 ------------
                                (CUSIP Number)

                               December 31, 2005
--------------------------------------------------
           (Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

    [ ]  Rule 13d-1(b)

    [X]  Rule 13d-1(c)

    [ ]  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).


                                 SCHEDULE 13G

CUSIP NO. 131722100                                                 Page 2 of 6
__________________________________________________
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)
1
    Michael A. Roth and Brian J. Stark, as joint filers pursuant to
    Rule 13d-1(k)
__________________________________________________
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP                (a) [X]
                                                                    (b) [ ]
__________________________________________________
3    SEC USE ONLY
__________________________________________________
4    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America
__________________________________________________

NUMBER OF      5    SOLE VOTING POWER

SHARES              0
              __________________________________________________
BENEFICIALLY   6    SHARED VOTING POWER

OWNED BY            14,963,654 shares of Common Stock (See Item 4)
              __________________________________________________
EACH           7    SOLE DISPOSITIVE POWER

REPORTING           0
              __________________________________________________
PERSON         8    SHARED DISPOSITIVE POWER

WITH                14,963,654 shares of Common Stock (See Item 4)
__________________________________________________
9    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    14,963,654 shares of Common Stock (See Item 4)
__________________________________________________
10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
                                                                         [X]
__________________________________________________
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.3% (See Item 4)
__________________________________________________
12   TYPE OF REPORTING PERSON

    IN
__________________________________________________

                                 SCHEDULE 13G

CUSIP NO. 131722100                                                 Page 3 of 6

Item 1(a).     Name of Issuer:

              Calypte Biomedical Corporation (the "Issuer")

Item 1(b).     Address of Issuer's Principal Executive Offices:

              1265 Harbor Bay Parkway
              Alameda, California 94502

Items 2(a),
(b) and (c).   Name of Persons Filing, Address of Principal Business Office and
              Citizenship:

              This Amendment No. 2 to Schedule 13G is being filed on behalf of
              Michael A. Roth and Brian J. Stark, as joint filers
              (collectively, the "Reporting Persons").

              The Reporting Persons have entered into a Joint Filing Agreement,
              a copy of which is filed with this Amendment No. 2 to Schedule
              13G as Exhibit 1, pursuant to which the Reporting Persons have
              agreed to file this Amendment No. 2 to Schedule 13G jointly in
              accordance with the provisions of Rule 13d-1(k) of the Securities
              Exchange Act of 1934, as amended.

              The principal business office of the Reporting Persons is 3600
              South Lake Drive, St. Francis, WI 53235.

Item 2(d).     Title of Class of Securities:

              Common Stock, par value $0.03 per share, of the Issuer (the
              "Common Stock")

Item 2(e).     CUSIP Number:

              131722100

Item 3.        Not applicable.

Item 4.        Ownership.

              (a)  Amount beneficially owned:

                   14,963,654 shares of Common Stock*

              (b)  Percent of class:

                   Based on 181,016,276 shares of Common Stock of the Issuer
                   outstanding as of November 11, 2005 (as set forth in the
                   Issuer's 10-QSB for the quarterly period ended September 30,
                   2005), the Reporting Persons hold approximately 8.3%* of the
                   issued and outstanding Common Stock of the Issuer.

              (c)  Number of shares to which such person has:

                                 SCHEDULE 13G

CUSIP NO. 131722100                                                 Page 4 of 6

                   (i)   Sole power to vote or direct the vote: 0

                   (ii)  Shared power to vote or direct the vote: 14,963,654
                         shares of Common Stock*

                   (iii) Sole power to dispose or to direct the disposition of:
                         0

                   (iv)  Shared power to dispose of or direct the disposition
                         of: 14,963,654 shares of Common Stock*

              *The Reporting Persons beneficially own an aggregate of
              14,963,654 shares of Common Stock. The foregoing amount of Common
              Stock and percentage ownership represent the combined indirect
              holdings of Michael A. Roth and Brian J. Stark. The shares of
              Common Stock reported in this Amendment No. 2 to Schedule 13G do
              not include certain shares of Common Stock issuable upon the
              exercise of warrants held by the Reporting Persons. Such warrants
              held by the Reporting Persons are subject to conversion caps that
              preclude the holder thereof from utilizing its exercise rights to
              the extent that it would beneficially own (determined in
              accordance with Section 13(d) of the Securities Exchange Act of
              1934 (the "Exchange Act")) in excess of 4.99% of the Common
              Stock, giving effect to such exercise.

              All of the foregoing represents an aggregate of 14,963,654 shares
              of Common Stock held directly by SF Capital Partners, Ltd. ("SF
              Capital"). The Reporting Persons are the Managing Members of
              Stark Offshore Management, LLC ("Stark Offshore"), which acts as
              investment manager and has sole power to direct the management of
              SF Capital. Through Stark Offshore, the Reporting Persons possess
              voting and dispositive power over all of the foregoing shares.
              Therefore, for the purposes of Rule 13d-3 under the Exchange Act,
              the Reporting Persons may be deemed to be the beneficial owners
              of, but hereby disclaim such beneficial ownership of, the
              foregoing shares.

Item 5.        Ownership of Five Percent or Less of a Class.

              Not applicable.

Item 6.        Ownership of More than Five Percent on Behalf of Another Person.

              Not applicable

Item 7.        Identification and Classification of the Subsidiary Which
              Acquired the Security Being Reported By the Parent Holding
              Company.

              Not applicable

Item 8.        Identification and Classification of Members of the Group.

              Not applicable

                                 SCHEDULE 13G

CUSIP NO. 131722100                                                 Page 5 of 6

Item 9.        Notice of Dissolution of a Group.

              Not applicable.

Item 10.       Certification.

              By signing below I certify that, to the best of my knowledge and
              belief, the securities referred to above were not acquired and
              are not held for the purpose of or with the effect of changing or
              influencing the control of the issuer of the securities and were
              not acquired and are not held in connection with or as a
              participant in any transaction having that purpose or effect.


                                 SCHEDULE 13G

CUSIP NO. 131722100                                                 Page 6 of 6

                                   SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

Dated:  February 14, 2006


                                       /s/ Michael A. Roth
                                       -----------------------
                                       Michael A. Roth

                                       /s/ Brian J. Stark
                                       -----------------------
                                       Brian J. Stark


                                 SCHEDULE 13G

CUSIP NO. 131722100

                                                                      Exhibit 1

                            JOINT FILING AGREEMENT

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934,
as amended, the undersigned agree to the joint filing on behalf of each of them
of a statement on Schedule 13G (including amendments thereto) with respect to
14,963,654 shares of Common Stock, par value $0.03 per share, of Calypte
Biomedical Corporation and further agree that this Joint Filing Agreement shall
be included as an exhibit to such joint filings.

    The undersigned further agree that each party hereto is responsible for the
timely filing of such Schedule 13G and any amendments thereto, and for the
completeness and accuracy of the information concerning such party contained
therein; provided, however, that no party is responsible for the completeness or
accuracy of the information concerning any other party making the filing, unless
such party knows or has reason to believe that such information is inaccurate.

    IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement
on February 14, 2006.


                                       /s/ Michael A. Roth
                                       -----------------------
                                       Michael A. Roth


                                       /s/ Brian J. Stark
                                       -----------------------

quelle: http://www.sec.gov/Archives/edgar/data/899426/...feb_13ga-calypte.txt

mfg kram  

 

http://phx.corporate-ir.net/phoenix.zhtml?c=97535&p=irol-sec

mfg kram  

 

 

eure leicht verbesserte charttechnik:


Support/Resistance
Type Value Conf.
resist. 0.31 2
resist. 0.29 2
resist. 0.28 10
resist. 0.25 8
resist. 0.24 3
resist. 0.22 7
resist. 0.21 6
supp 0.20 16
supp 0.19 20
supp 0.18 10
supp 0.17 16
supp 0.16 46
supp 0.15 4
supp 0.13 8  

0.21 1400 NLS 15:59:40
0.21 2500 MID 15:59:20
0.21 2500 MID 15:59:20
0.21 25000 AMX 15:59:18
0.21 200 NSX 15:57:13
0.21 200 PAC 15:57:13
0.21 10600 NSX 15:56:31
0.21 10600 PAC 15:56:30
0.21 4400 PAC 15:56:30
0.21 7100 PAC 15:52:31
0.21 10000 PAC 15:50:58
0.21 100 NLS 15:50:58
0.21 1400 NSX 15:50:58
0.21 1400 PAC 15:50:58
0.21 1400 PAC 15:50:58
0.21 100 PAC 15:50:58
0.21 100 PAC 15:50:58
0.21 100 PAC 15:50:58
0.21 100 PAC 15:50:58
0.21 100 PAC 15:50:57
0.21 100 PAC 15:50:57
0.21 100 PAC 15:50:57
0.21 100 PAC 15:50:57
0.21 100 PAC 15:50:57
0.21 100 PAC 15:50:57
0.21 100 PAC 15:50:57
0.21 100 PAC 15:50:57
0.21 100 PAC 15:50:57
0.21 100 PAC 15:50:57


heute müssen eure zahlen kommen, ich denke, dann seht ihr die 0,20$ von unten...  

Calypte Announces American Stock Exchange Hearinghttp://biz.yahoo.com/prnews/060216/nyth015.html?.v=43  

....es schweigen die Vöglein im Walde. Keine Charttechnik, keine News, keine Zahlen, keine Umsätze - was ist heute denn los?  

 

ja und Michael E. Roth ist drin, Montag Feiertag und Dienstag ist wieder Newstag,
im diesen Sinne macht euch nicht verrückt alles geht seinen Weg.
Schönes WE, Lucky  

spätestens im März werden wir aus China Nachrichten zu hören bekommen, schönes WE auch.  

3600 South Lake Drive • St. Francis, WI 53235-3716 • Phone: 414.294.7000 • Email: info@starkinvestments.com
Stark Investment also 14.500.000 haben die von Caly eingesackt !.

Items 2(a),
(b) and (c).   Name of Persons Filing, Address of Principal Business Office and
              Citizenship:

              This Amendment No. 2 to Schedule 13G is being filed on behalf of
              Michael A. Roth and Brian J. Stark, as joint filers
              (collectively, the "Reporting Persons").

              The Reporting Persons have entered into a Joint Filing Agreement,
              a copy of which is filed with this Amendment No. 2 to Schedule
              13G as Exhibit 1, pursuant to which the Reporting Persons have
              agreed to file this Amendment No. 2 to Schedule 13G jointly in
              accordance with the provisions of Rule 13d-1(k) of the Securities
              Exchange Act of 1934, as amended.

              The principal business office of the Reporting Persons is 3600
              South Lake Drive, St. Francis, WI 53235.

 

Calypte hat als einzigen den Schnelltest auf Urinbasis Richtig ?

Nun schaut euch das an ?
http://www.freewebs.com/asialionbiotech/ Catalogue



Asialionbiotech

¡¡ 4/F,Building A, 48 Yinhua Road, Xiangzhou, Zhuhai, CHINA

Tel:+86-756-2267514   Fax:+86-756-2267374

E-mail:asialionbiotech@yahoo.com

Website: www.asialionbiotech.com


--------------------------------------------------

 

Artikel und Reserchen über China und Hiv und Caly rein,

China erlässt Anti-AIDS-Gesetz

12.02.2006 | 16:12:02

PEKING – Die chinesische Regierung hat heute ein Aids-Gesetz zur Verhinderung und Eindämmung der Immunschwächekrankheit erlassen. In dem vom Staatsrat verabschiedeten Gesetz werden HIV-Infizierte und Aids-Patienten vor Diskriminierung geschützt, zugleich wird die bewusste Verbreitung des tödlichen Virus´ unter Strafe gestellt, wie die amtliche Nachrichtenagentur Xinhua berichtete. Das Gesetz soll am 1. März in Kraft treten. Es verpflichtet die Provinzregierungen, mittellose Patienten mit Medikamenten zu versorgen. Auch die Behandlung und Beratung von infizierten Schwangeren muss von der Regierung gesichert werden. Vor einem Monat gab Peking bekannt, dass sich 2005 70’000 Menschen mit dem HIV-Virus infizierten.

 

 

 

noch fester drauf nageln!


Asia-lion Biotechnology Co.,Ltd.


Company Profile



Business Type: Manufacturer
Year Established: 1991
Industry Focus: > Health & Beauty > Bio-technology Products
Products/Services We Offer: HBsAg, HIV, HCV, HAV ELISA kits and fertility, infectious disease, cardiac marker, tumor marker rapid tests.
Main Markets: China, Asia, Africa, America, EU
Other Markets:
OEM Service: available
R&D Staff: 51 - 100 People
Legal Representative / CEO: Xianjie LIU
Number of Employees: 101 - 500 People
Annual Turnover: US$1 Million - US$2.5 Million
Certificate: GMP, ISO9001




http://product.globalimporter.net/china-exporter/51116/Asia%...



caly ist einfach zu langsam, andere ziehen nach bzw. überholen sie, klar auch, wenn man sich nur auf den verkauf von aktien beschränkt, anstatt mal ein richtiges produkt an den mann zu bringen...muhahahahahahahaa...  

Support/Resistance
Type Value Conf.
resist. 0.31 2
resist. 0.29 2
resist. 0.28 10
resist. 0.25 10
resist. 0.23 3
resist. 0.22 7
resist. 0.21 6
resist. 0.20 14
supp 0.19 20
supp 0.18 14
supp 0.17 16
supp 0.16 46


jetzt schon mit widerständen bei 0,20$...es wird zeit, das sinkende schiff endlich zu verlassen...  

Time & Sales
Price Size Exch Time
0.20 23700 AMX 16:00:02
0.21 600 AMX 15:59:58
0.21 600 AMX 15:58:48
0.21 6800 NSX 15:58:17
0.21 6800 PAC 15:58:17
0.21 200 PAC 15:58:17
0.21 500 NLS 15:58:17
0.20 10000 NLS 15:57:52
0.20 300 NSX 15:56:10
0.20 300 PAC 15:56:09
0.21 600 AMX 15:53:39
0.21 700 NLS 15:53:28
0.20 25000 AMX 15:50:54
0.20 500 NSX 15:42:36
0.21 4900 NLS 15:23:54
0.21 3600 NLS 15:23:52
0.21 50000 NLS 15:22:20
0.20 43000 AMX 15:19:33
0.21 2800 NLS 15:07:08
0.21 2000 NLS 14:56:17
0.21 900 NLS 14:47:45
0.20 1700 AMX 14:47:37
0.21 6500 NLS 14:44:04
0.21 100 NLS 14:44:04
0.21 100 NLS 14:44:04
0.21 100 NLS 14:44:04
0.21 100 NLS 14:44:04
0.21 100 NLS 14:44:04
0.21 100 NLS 14:44:04
0.21 100 NLS 14:44:04

durchschnittshandelskurs: 0.2028$  

recherchiert:

ihr werdet mit dem teil absaufen, weil caly angeblich heeren absichten viel zu langsam umgestzt werden. warum auch? aktien verkaufen im namen der moral und ethik ist doch viel einfacher oder?

besonders, wenn ein paar unbelehrbare deppen immer noch dran glauben...  

http://product.globalimporter.net/china-exporter/...td%2E/profile.htm  

10.000.000  Anteile sich gekrault !
oder sehe ich das falsch ?



SEC Filings
SC 13G/A
CALYPTE BIOMEDICAL CORP filed this Form SC 13G/A on 02/14/05
Entire Document
 << Previous Page | Next Page >>


                      SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, DC 20549

                                 SCHEDULE 13G
                                (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES
    13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

                              (Amendment No. 1)*

                        Calypte Biomedical Corporation
                        ------------------------------
                               (Name of Issuer)

                    Common Stock, par value $0.03 per share
                    ---------------------------------------
                        (Title of Class of Securities)

                                   131722100
                                 ------------
                                (CUSIP Number)

                               December 31, 2004
--------------------------------------------------
           (Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

    [ ]  Rule 13d-1(b)

    [X]  Rule 13d-1(c)

    [ ]  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).



                                 SCHEDULE 13G

CUSIP NO. 131722100                                                 Page 2 of 6
__________________________________________________
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)
1
    Michael A. Roth and Brian J. Stark, as joint filers pursuant to
    Rule 13d-1(k)
__________________________________________________
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP                (a) [X]
                                                                    (b) [ ]
__________________________________________________
3    SEC USE ONLY
__________________________________________________
4    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America
__________________________________________________

NUMBER OF      5    SOLE VOTING POWER

SHARES              0
              __________________________________________________
BENEFICIALLY   6    SHARED VOTING POWER

OWNED BY            10,000,000 (See Item 4)
              __________________________________________________
EACH           7    SOLE DISPOSITIVE POWER

REPORTING           0
              __________________________________________________
PERSON         8    SHARED DISPOSITIVE POWER

WITH                10,000,000 (See Item 4)
__________________________________________________
9    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,000,000 (See Item 4)
__________________________________________________
10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
                                                                         [X]
__________________________________________________
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.0% (See Item 4)
__________________________________________________
12   TYPE OF REPORTING PERSON

    IN
__________________________________________________


                                 SCHEDULE 13G

CUSIP NO. 131722100                                                 Page 3 of 6

Item 1(a).     Name of Issuer:

              Calypte Biomedical Corporation (the "Issuer")

Item 1(b).     Address of Issuer's Principal Executive Offices:

              1265 Harbor Bay Parkway
              Alameda, California 94502

Items 2(a),
(b) and (c).   Name of Persons Filing, Address of Principal Business Office and
              Citizenship:

              This Amendment No. 1 to Schedule 13G is being filed on behalf of
              Michael A. Roth and Brian J. Stark, as joint filers
              (collectively, the "Reporting Persons").

              The Reporting Persons have entered into a Joint Filing Agreement,
              a copy of which is filed with this Amendment No. 1 to Schedule
              13G as Exhibit 1, pursuant to which the Reporting Persons have
              agreed to file this Amendment No. 1 to Schedule 13G jointly in
              accordance with the provisions of Rule 13d-1(k) of the Securities
              Exchange Act of 1934, as amended.

              The principal business office of the Reporting Persons is 3600
              South Lake Drive, St. Francis, WI 53235.

Item 2(d).     Title of Class of Securities:

              Common Stock, par value $0.03 per share, of the Issuer (the
              "Common Stock")

Item 2(e).     CUSIP Number:

              131722100

Item 3.        Not applicable.

Item 4.        Ownership.

              (a)  Amount beneficially owned:

                   10,000,000 shares of Common Stock*

              (b)  Percent of class:

                   Based on 168,044,755 shares of Common Stock of the Issuer
                   outstanding as of August 6, 2004 (as set forth in the
                   Issuer's 10-QSB Amend. No. 1 for the quarterly period ended
                   June 30, 2004), the Reporting Persons hold approximately
                   6.0%* of the issued and outstanding Common Stock of the
                   Issuer.

              (c)  Number of shares to which such person has:

                                 SCHEDULE 13G

CUSIP NO. 131722100                                                 Page 4 of 6

                   (i)   Sole power to vote or direct the vote: 0

                   (ii)  Shared power to vote or direct the vote: 10,000,000*

                   (iii) Sole power to dispose or to direct the disposition of:
                         0

                   (iv)  Shared power to dispose of or direct the disposition
                         of: 10,000,000*

                   *The Reporting Persons beneficially own an aggregate of
                   10,000,000 shares of Common Stock. The foregoing amount of
                   Common Stock and percentage ownership represent the combined
                   indirect holdings of Michael A. Roth and Brian J. Stark. The
                   shares of Common Stock reported in this Schedule 13G do not
                   include certain shares of Common Stock issuable upon the
                   exercise of warrants held by the Reporting Persons. Such
                   warrants held by the Reporting Persons are subject to
                   conversion caps that preclude the holder thereof from
                   utilizing its exercise rights to the extent that it would
                   beneficially own (determined in accordance with Section
                   13(d) of the Securities Exchange Act of 1934 (the "Exchange
                   Act")) in excess of 4.999% of the Common Stock, giving
                   effect to such exercise.

                   All of the foregoing represents an aggregate of 10,000,000
                   shares of Common Stock held directly by SF Capital Partners
                   Ltd. ("SF Capital"). The Reporting Persons are the Managing
                   Members of Stark Offshore Management, LLC ("Stark
                   Offshore"), which acts as investment manager and has sole
                   power to direct the management of SF Capital. Through Stark
                   Offshore, the Reporting Persons possess voting and
                   dispositive power over all of the foregoing shares.
                   Therefore, for the purposes of Rule 13d-3 under the Exchange
                   Act, the Reporting Persons may be deemed to be the
                   beneficial owners of, but hereby disclaim such beneficial
                   ownership of, the foregoing shares.

Item 5.        Ownership of Five Percent or Less of a Class.

              Not applicable.

Item 6.        Ownership of More than Five Percent on Behalf of Another Person.

              Not applicable

Item 7.        Identification and Classification of the Subsidiary Which
              Acquired the Security Being Reported By the Parent Holding
              Company.

              Not applicable

Item 8.        Identification and Classification of Members of the Group.

              Not applicable

Item 9.        Notice of Dissolution of a Group.

                                 SCHEDULE 13G

CUSIP NO. 131722100                                                 Page 5 of 6

              Not applicable.

Item 10.       Certification.

              By signing below I certify that, to the best of my knowledge and
              belief, the securities referred to above were not acquired and
              are not held for the purpose of or with the effect of changing or
              influencing the control of the issuer of the securities and were
              not acquired and are not held in connection with or as a
              participant in any transaction having that purpose or effect.



                                 SCHEDULE 13G

CUSIP NO. 131722100                                                 Page 6 of 6

                                   SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

Dated:   February 14, 2005


                                       /s/ Michael A. Roth
                                       -----------------------
                                       Michael A. Roth

                                       /s/ Brian J. Stark
                                       -----------------------
                                       Brian J. Stark



                                 SCHEDULE 13G

CUSIP NO. 131722100

                                                                      Exhibit 1

                            JOINT FILING AGREEMENT

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934,
as amended, the undersigned agree to the joint filing on behalf of each of them
of a statement on Schedule 13G (including amendments thereto) with respect to
10,000,000 shares of Common Stock, par value $0.03 per share, of Calypte
Biomedical Corporation and further agree that this Joint Filing Agreement shall
be included as an exhibit to such joint filings.

    The undersigned further agree that each party hereto is responsible for the
timely filing of such Schedule 13G and any amendments thereto, and for the
completeness and accuracy of the information concerning such party contained
therein; provided, however, that no party is responsible for the completeness or
accuracy of the information concerning any other party making the filing, unless
such party knows or has reason to believe that such information is inaccurate.

    IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement
on February 14, 2005.


                                       /s/ Michael A. Roth
                                       -----------------------
                                       Michael A. Roth


                                       /s/ Brian J. Stark
                                       -----------------------
                                       Brian J. Stark